📷 Image: Wikimedia Commons / Abidlone
Business
Lupin Receives Single USFDA Observation at Goa Facility
✍️ Sahi
🗓 25 Oct 2026, 12:18 PM
👁 15
Indian drugmaker Lupin has been issued one observation by the U.S. Food and Drug Administration concerning its manufacturing site in Goa, according to a report by Sahi. The observation highlights a compliance issue that the company must address.
Lupin Limited, a leading Indian pharmaceutical company, received a single observation from the U.S. Food and Drug Administration (USFDA) regarding its manufacturing facility in Goa.
The observation, issued by the USFDA's Office of Regulatory Affairs, points to a specific compliance concern that the company must rectify to maintain its Good Manufacturing Practice (GMP) certification.
Lupin has stated it will cooperate fully with the regulator and will implement corrective actions promptly.
The company has previously faced regulatory scrutiny in other jurisdictions, but this is the first USFDA observation for its Goa plant.
The observation, issued by the USFDA's Office of Regulatory Affairs, points to a specific compliance concern that the company must rectify to maintain its Good Manufacturing Practice (GMP) certification.
Lupin has stated it will cooperate fully with the regulator and will implement corrective actions promptly.
The company has previously faced regulatory scrutiny in other jurisdictions, but this is the first USFDA observation for its Goa plant.